Skip to main content

Research Repository

Advanced Search

Development of a core set of outcome measures for large-vessel vasculitis: Report from OMERACT 2016

Sreih, Antoine G.; Alibaz-Oner, Fatma; Kermani, Tanaz A.; Aydin, Sibel Z.; Cronholm, Peter F.; Davis, Trocon; Easley, Ebony; Gul, Ahmet; Mahr, Alfred; McAlear, Carol A.; Milman, Nataliya; Robson, Joanna C.; Tomasson, Gunnar; Direskeneli, Haner; Merkel, Peter A.

Development of a core set of outcome measures for large-vessel vasculitis: Report from OMERACT 2016 Thumbnail


Authors

Antoine G. Sreih

Fatma Alibaz-Oner

Tanaz A. Kermani

Sibel Z. Aydin

Peter F. Cronholm

Trocon Davis

Ebony Easley

Ahmet Gul

Alfred Mahr

Carol A. McAlear

Nataliya Milman

Jo Robson Jo.Robson@uwe.ac.uk
Consultant Associate Professor in Rheumatology

Gunnar Tomasson

Haner Direskeneli

Peter A. Merkel



Abstract

Copyright © 2017. All rights reserved. Objective. Among the challenges in conducting clinical trials in large-vessel vasculitis (LVV), including both giant cell arteritis (GCA) and Takayasu arteritis (TA), is the lack of standardized and meaningful outcome measures. The Outcome Measures in Rheumatology (OMERACT) Vasculitis Working Group initiated an international effort to develop and validate data-driven outcome tools for clinical investigation in LVV. Methods.An international Delphi exercise was completed to gather opinions from clinical experts on LVV-related domains considered important to measure in trials. Patient interviews and focus groups were completed to identify outcomes of importance to patients. The results of these activities were presented and discussed in a "Virtual Special Interest Group" using telephone- and Internet-based conferences, discussions through electronic mail, and an in-person session at the 2016 OMERACT meeting. A preliminary core set of domains common for all forms of LVV with disease-specific elements was proposed. Results. The majority of experts agree with using common outcome measures for GCA and TA, with the option of supplementation with disease-specific items. Following interviews and focus groups, pain, fatigue, and emotional effect emerged as health-related quality of life domains important to patients. Current disease assessment tools, including the Birmingham Vasculitis Activity Score, were found to be inadequate to assess disease activity in GCA and standardized assessment of imaging tests were felt crucial to study LVV, especially TA. Conclusion. Initial data from a clinician Delphi exercise and structured patient interviews have provided themes toward an OMERACT-endorsed core set of domains and outcome measures.

Citation

Sreih, A. G., Alibaz-Oner, F., Kermani, T. A., Aydin, S. Z., Cronholm, P. F., Davis, T., …Merkel, P. A. (2017). Development of a core set of outcome measures for large-vessel vasculitis: Report from OMERACT 2016. Journal of Rheumatology, 44(12), 1933-1937. https://doi.org/10.3899/jrheum.161467

Journal Article Type Article
Acceptance Date Jun 17, 2017
Online Publication Date Dec 1, 2017
Publication Date Dec 1, 2017
Deposit Date Sep 12, 2017
Publicly Available Date Sep 1, 2018
Journal Journal of Rheumatology
Print ISSN 0315-162X
Electronic ISSN 1499-2752
Publisher Journal of Rheumatology
Peer Reviewed Peer Reviewed
Volume 44
Issue 12
Pages 1933-1937
DOI https://doi.org/10.3899/jrheum.161467
Keywords giant cell arteritis, takayasu arteritis, vasculitis outcome assessment
Public URL https://uwe-repository.worktribe.com/output/903554
Publisher URL http://dx.doi.org/10.3899/jrheum.161467

Files






You might also like



Downloadable Citations